huGPC1-HEK293 is a recombinant human glypican-1 (GPC1) protein expressed in HEK293 cells. It is primarily used in biomedical research and drug development, particularly in cancer studies. GPC1 is a cell surface proteoglycan involved in key signaling pathways such as Wnt, Hedgehog, and growth factor signaling, which regulate cell proliferation and differentiation. Due to its overexpression in various cancers—including pancreatic, breast, and glioblastoma—huGPC1-HEK293 serves as a critical tool for studying tumor biology and identifying potential therapeutic targets. This protein is widely used in immunoassay development, such as ELISA and flow cytometry, to generate or validate anti-GPC1 antibodies. It also supports research into GPC1-based biomarkers for early cancer detection, especially in liquid biopsies where GPC1-positive exosomes are analyzed. In addition, huGPC1-HEK293 is employed in binding and neutralization studies for antibody-drug conjugates (ADCs) and CAR-T cell therapies, helping assess target engagement and efficacy. Its proper post-translational modifications, enabled by the HEK293 expression system, ensure high biological relevance in functional studies.